Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Dodick

Showing results (241-250 of 365) with videos related to

Pageof 37
Sort By:
Mayo Clinic Proceedings|July 22, 2023
Prevalence of and Risk Factors for Post-traumatic Headache in Civilian Patients After Mild Traumatic Brain Injury: A TRACK-TBI StudyHåkan Ashina, David W Dodick, Jason Barber, et al.
Cephalalgia : an International Journal of Headache|August 19, 2021
Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studiesRichard B Lipton, David W Dodick, David Kudrow, et al.
Headache|February 1, 2008
Predictors of migraine headache recurrence: a pooled analysis from the eletriptan databaseDavid W Dodick, Richard B Lipton, Peter J Goadsby, et al.
Headache|February 12, 2014
Education and decision making at the time of triptan prescribing: patient expectations vs actual practicePaul G Mathew, Jelena M Pavlovic, Alyssa Lettich, et al.
Headache|March 4, 2025
Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database-based observational cohort studyDavid W Dodick, Stewart J Tepper, Jessica Ailani, et al.
Cephalalgia : an International Journal of Headache|February 24, 2018
ARISE: A Phase 3 randomized trial of erenumab for episodic migraineDavid W Dodick, Messoud Ashina, Jan Lewis Brandes, et al.
Headache|September 5, 2013
Identifying the factors underlying discontinuation of triptansRebecca E Wells, Shira Y Markowitz, Eric P Baron, et al.
Neurology|June 10, 2016
TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time pointsMarcelo E Bigal, David W Dodick, Abouch V Krymchantowski, et al.
Brain : a Journal of Neurology|March 24, 2022
Dysregulation of serum prolactin links the hypothalamus with female nociceptors to promote migraineMoe Watanabe, Caroline M Kopruszinski, Aubin Moutal, et al.
Headache|February 17, 2021
Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) studyAriane K Kawata, Neel Shah, Jiat-Ling Poon, et al.
Pageof 37

Showing results (241-250 of 365) with videos related to

Sort By:
Pageof 37
Mayo Clinic Proceedings|July 22, 2023
Prevalence of and Risk Factors for Post-traumatic Headache in Civilian Patients After Mild Traumatic Brain Injury: A TRACK-TBI StudyHåkan Ashina, David W Dodick, Jason Barber, et al.
Cephalalgia : an International Journal of Headache|August 19, 2021
Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studiesRichard B Lipton, David W Dodick, David Kudrow, et al.
Headache|February 1, 2008
Predictors of migraine headache recurrence: a pooled analysis from the eletriptan databaseDavid W Dodick, Richard B Lipton, Peter J Goadsby, et al.
Headache|February 12, 2014
Education and decision making at the time of triptan prescribing: patient expectations vs actual practicePaul G Mathew, Jelena M Pavlovic, Alyssa Lettich, et al.
Headache|March 4, 2025
Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database-based observational cohort studyDavid W Dodick, Stewart J Tepper, Jessica Ailani, et al.
Cephalalgia : an International Journal of Headache|February 24, 2018
ARISE: A Phase 3 randomized trial of erenumab for episodic migraineDavid W Dodick, Messoud Ashina, Jan Lewis Brandes, et al.
Headache|September 5, 2013
Identifying the factors underlying discontinuation of triptansRebecca E Wells, Shira Y Markowitz, Eric P Baron, et al.
Neurology|June 10, 2016
TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time pointsMarcelo E Bigal, David W Dodick, Abouch V Krymchantowski, et al.
Brain : a Journal of Neurology|March 24, 2022
Dysregulation of serum prolactin links the hypothalamus with female nociceptors to promote migraineMoe Watanabe, Caroline M Kopruszinski, Aubin Moutal, et al.
Headache|February 17, 2021
Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) studyAriane K Kawata, Neel Shah, Jiat-Ling Poon, et al.
Pageof 37